| Name | Title | Contact Details |
|---|
Stardust Power Inc. is developing a strategically central, vertically-integrated lithium refinery capable of producing 50,000 tons per annum of battery-grade lithium. Committed to sustainability at each point in the process, the company enjoys a diversified supply of lithium from American brine sources. Stardust is comprised of leading industry, mining and finance experts, supported by a best-in-class advisory board and top technology partners. For more information, visit www.stardust-power.com.
Phillip Jeffries Ltd is a family-run company that specializes in the manufacture and importation of high-quality, unique, and textured wallcoverings. Founded in 1976 by Eric Bershad, the company has established itself as a global leader in the industry, offering an extensive range of over 1,000 natural wallcoverings. Their product lineup includes Japanese paper weaves, gold leaf, grasscloth, silks, and unique hand-crafted specialties, all crafted by skilled artisans to ensure exceptional quality and aesthetic appeal. The company is led by Eric Bershads sons, Philip and Jeffrey Bershad, who serve as President and Chief Executive Officer, respectively. This family involvement helps maintain the companys mission and values. Phillip Jeffries is known for its commitment to fast delivery, making it a preferred choice for interior designers, architects, and high-end homeowners seeking distinctive wallcovering solutions.
At Flow, AI isnt just a feature—its the core of everything we do. We are transforming the wholesale insurance industry by building a futuristic insurance brokerage where AI powers every aspect of the experience. With advanced AI features already live in production and actively used by our brokers, we are pioneering Wholesale 3.0, equipping brokers with cutting-edge tools to provide unparalleled service. We are creating an ecosystem of AI agents designed to streamline processes and enhance decision-making in the insurance landscape. The industry relies heavily on text—emails, files, and documents—making Generative AI a perfect fit for solving its challenges. Flow leverages AI to deliver meaningful insights, deep analysis, and white-glove support for every transaction, no matter the deal size. By combining human expertise with Platformless AI, we are bringing back the art of wholesale insurance while eliminating the need for outdated portals. In the past seven months, weve grown 250% month-over-month(!) and are forecasting even more massive growth. Were a Series A startup with over $20M raised from top investors like Lightspeed, MunichRe Ventures, and industry angels.
Estiatorio Milos is a renowned restaurant group founded in 1979 by Greek restaurateur Costas Spiliadis in Montreal. It is celebrated for its authentic Greek cuisine, emphasizing high-quality, fresh ingredients. With locations in major cities like New York, Athens, Las Vegas, Miami, London, Los Cabos, and Dubai, Milos offers refined dining experiences that prioritize simplicity and the art of sharing. The restaurant specializes in Mediterranean seafood, featuring fresh fish and shellfish sourced directly from Greek fishermen. Dishes are crafted to highlight natural flavors, often using artisanal ingredients like cold-pressed Koroneiki olive oil and seasonal vegetables. Milos is known for its warm hospitality and communal dining atmosphere, making it a favorite among discerning diners and culinary enthusiasts seeking an authentic taste of Greece.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.